{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:47:10Z","timestamp":1785930430153,"version":"3.56.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bulcan.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:22:07Z","timestamp":1785928927000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prise en charge de la GVH chronique pulmonaire en 2025, indication de la transplantation pulmonaire (SFGM-TC)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9294-5340","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Salvator","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Mamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Catherinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Wallyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0415","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0420","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2026.04.011_bib0425","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1164\/rccm.202506-1352ST","article-title":"Addressing knowledge gaps in the early detection of bronchiolitis obliterans syndrome after hematopoietic cell transplantation: an official American Thoracic Society Research Statement","volume":"211","author":"Cheng","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.011_bib0430","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0435","doi-asserted-by":"crossref","first-page":"2301727","DOI":"10.1183\/13993003.01727-2023","article-title":"ERS\/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults","volume":"63","author":"Bos","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bulcan.2026.04.011_bib0440","doi-asserted-by":"crossref","first-page":"100209","DOI":"10.1016\/j.jhlto.2025.100209","article-title":"Lung transplantation for pulmonary chronic graft-versus-host disease: a missed opportunity?","volume":"7","author":"Zajacova","year":"2025","journal-title":"JHLT Open"},{"issue":"11S","key":"10.1016\/j.bulcan.2026.04.011_bib0445","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0450","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00185-2022","article-title":"Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions","author":"Glanville","year":"2022","journal-title":"ERJ Open Res"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0455","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1513\/AnnalsATS.201604-262OC","article-title":"Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant","volume":"13","author":"Cheng","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0460","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/his.13697","article-title":"Lung histopathology of non-infectious pulmonary complications after allogeneic haematopoietic stem cell transplantation","volume":"73","author":"Meignin","year":"2018","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.011_bib0475","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/bmt.2012.241","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis","volume":"48","author":"Bergeron","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.04.011_bib0470","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/COPD.S453086","article-title":"Preserved Ratio Impaired Spirometry (PRISm): a global epidemiological overview, radiographic characteristics, comorbid associations, and differentiation from chronic obstructive pulmonary disease","volume":"19","author":"Huang","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.011_bib0465","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.011_bib0480","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.bbmt.2015.02.006","article-title":"Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung","volume":"21","author":"Abedin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0485","doi-asserted-by":"crossref","first-page":"1702617","DOI":"10.1183\/13993003.02617-2017","article-title":"Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation","volume":"51","author":"Bergeron","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0490","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41409-022-01859-4","article-title":"Interstitial lung diseases after hematopoietic stem cell transplantation: new pattern of lung chronic graft-versus-host disease?","volume":"58","author":"Archer","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.011_bib0495","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.rmed.2014.09.006","article-title":"Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation","volume":"108","author":"Schlemmer","year":"2014","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0500","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41409-019-0636-8","article-title":"Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation","volume":"55","author":"Bondeelle","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0505","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1513\/AnnalsATS.201902-181CME","volume":"16","author":"Chua","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0510","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bbmt.2018.11.022","article-title":"Pulmonary impairment after respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients","volume":"25","author":"Sheshadri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0515","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","article-title":"Reliability and validity of the modified 7-day Lee Chronic Graft-Versus-Host Disease Symptom Scale","volume":"26","author":"Teh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0520","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cells14040238","article-title":"Treatment response in individual organs affected by chronic graft-versus-host disease","volume":"14","author":"Morishita","year":"2025","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0525","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","article-title":"Budesonide\/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation","volume":"191","author":"Bergeron","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0530","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0535","first-page":"2649","article-title":"Therapeutic effect of budesonide, montelukast and azithromycin on post-infectious bronchiolitis obliterans in children","volume":"20","author":"Chen","year":"2020","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12931-016-0380-1","article-title":"Therapeutic effect of budesonide\/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"17","author":"Kim","year":"2016","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0545","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12185-022-03517-3","article-title":"Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation","volume":"117","author":"Kambara","year":"2023","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.011_bib0550","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/bmt.2010.48","article-title":"Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT","volume":"45","author":"Ueda","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.011_bib0555","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0560","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2020.07.033","article-title":"Effect of ruxolitinib on lung function after allogeneic stem cell transplantation","volume":"26","author":"Bondeelle","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0565","doi-asserted-by":"crossref","first-page":"e2034750","DOI":"10.1001\/jamanetworkopen.2020.34750","article-title":"Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Wu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.bulcan.2026.04.011_bib0570","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1200\/JCO-24-02477","article-title":"Ruxolitinib in patients with corticosteroid-refractory or corticosteroid-dependent chronic graft-versus-host disease: 3-year final analysis of the phase III REACH3 study","volume":"43","author":"Zeiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0575","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.011_bib0580","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41409-019-0662-6","article-title":"Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease","volume":"55","author":"Streiler","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2026.04.011_bib0585","doi-asserted-by":"crossref","first-page":"668825","DOI":"10.3389\/fphar.2021.668825","article-title":"Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.011_bib0590","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/bloodadvances.2024014000","article-title":"A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT","volume":"9","author":"DeFilipp","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0595","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41409-024-02507-9","article-title":"Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment\u00a0\u2013\u00a0a retrospective, German-Swiss multicenter real-world data analysis","volume":"60","author":"Heidenreich","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.bulcan.2026.04.011_bib0600","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bulcan.2026.04.011_bib0605","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2026.04.011_bib0610","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.011_bib0615","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41409-025-02554-w","article-title":"Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"60","author":"Michonneau","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.011_bib0620","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0625","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.011_bib0630","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE Study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.011_bib0635","doi-asserted-by":"crossref","first-page":"867.e1","DOI":"10.1016\/j.jtct.2021.05.019","article-title":"An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease","volume":"27","author":"Doki","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.011_bib0640","doi-asserted-by":"crossref","first-page":"76.e1","DOI":"10.1016\/j.jtct.2024.11.004","article-title":"Systematic review and meta-analysis of extracorporeal photopheresis for the treatment of steroid-refractory chronic graft-versus-host disease","volume":"31","author":"DeFilipp","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.011_bib0645","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5045\/br.2014.49.2.100","article-title":"Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"49","author":"Malik","year":"2014","journal-title":"Blood Res"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0650","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/bmt.2015.324","article-title":"Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation","volume":"51","author":"Del Fante","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0655","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2010.152","article-title":"Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT","volume":"46","author":"Lucid","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0660","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.21404","article-title":"Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation","volume":"31","author":"Brownback","year":"2016","journal-title":"J Clin Apheresis"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.011_bib0665","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.bbmt.2018.04.012","article-title":"Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions","volume":"24","author":"Hefazi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.011_bib0670","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.bbmt.2016.08.027","article-title":"Azithromycin for the treatment of obliterative bronchiolitis after hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"22","author":"Yadav","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.011_bib0675","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/bmt.2011.1","article-title":"Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT\u00a0\u2013\u00a0a randomized double-blinded placebo-controlled study","volume":"46","author":"Lam","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.011_bib0680","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jama.2017.9938","article-title":"Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO Randomized Clinical Trial","volume":"318","author":"Bergeron","year":"2017","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.bulcan.2026.04.011_bib0685","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood.2022016926","article-title":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","volume":"140","author":"Vallet","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.011_bib0690","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbmt.2019.10.025","article-title":"Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation","volume":"26","author":"Cheng","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0695","doi-asserted-by":"crossref","first-page":"264.e1","DOI":"10.1016\/j.jtct.2022.01.021","article-title":"Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplantation and investigation into bronchiolitis obliterans syndrome pathogenesis","volume":"28","author":"Williams","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.011_bib0700","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.2023023249","article-title":"How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients","volume":"144","author":"Lai","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.011_bib0705","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bbmt.2011.11.031","article-title":"Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation","volume":"18","author":"Yanik","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.011_bib0710","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.bmt.1703303","article-title":"Morphologic changes leading to bronchiolitis obliterans in a patient with delayed non-infectious lung disease after allogeneic bone marrow transplantation","volume":"28","author":"Trisolini","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.011_bib0715","first-page":"e29195","article-title":"Concomitant ruxolitinib and ibrutinib for graft-versus-host disease (GVHD): the first reported use in pediatric patients","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Cureus"},{"issue":"Suppl. 1","key":"10.1016\/j.bulcan.2026.04.011_bib0720","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.rmr.2022.12.009","article-title":"[Lung transplantation for chronic graft-versus-host disease after hematopoietic stem cell transplantation]","volume":"40","author":"Brugi\u00e8re","year":"2023","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.bulcan.2026.04.011_bib0725","unstructured":"Agence de la biom\u00e9decine. Greffe cardio-pulmonaire et pulmonaire [Internet]. [cit\u00e9 27\u00a0d\u00e9c 2025. Disponible sur\u00a0: https:\/\/rams.agence-biomedecine.fr\/greffe-cardio-pulmonaire-et-pulmonaire-0]."},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.011_bib0730","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u00a0\u2013\u00a0an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0740","doi-asserted-by":"crossref","first-page":"E94","DOI":"10.1111\/j.1399-0012.2009.01155.x","article-title":"Solid organ transplantation in survivors of hematopoietic cell transplantation: a single institution case series and literature review","volume":"24","author":"Beitinjaneh","year":"2010","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2026.04.011_bib0745","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbmt.2014.04.008","article-title":"Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Cheng","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.011_bib0750","first-page":"5447","article-title":"Physical function after lung transplantation for late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Hamada","year":"2021","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.011_bib0755","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtcvs.2020.10.065","article-title":"Expanded indications for lung transplantation for pulmonary complications after hematopoietic stem cell transplantation","volume":"163","author":"Noguchi","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.011_bib0760","first-page":"227","article-title":"Lung transplantation for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a single-center experience","volume":"25","author":"Shitenberg","year":"2023","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.011_bib0765","doi-asserted-by":"crossref","first-page":"1701330","DOI":"10.1183\/13993003.01330-2017","article-title":"Lung transplantation after allogeneic stem cell transplantation: a pan-European experience","volume":"51","author":"Greer","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0770","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12931-021-01699-8","article-title":"Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant","volume":"22","author":"Riddell","year":"2021","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0775","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2015.12.023","article-title":"Correlation and agreement of handheld spirometry with laboratory spirometry in allogeneic hematopoietic cell transplant recipients","volume":"22","author":"Cheng","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0780","doi-asserted-by":"crossref","first-page":"1702328","DOI":"10.1183\/13993003.02328-2017","article-title":"Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant","volume":"52","author":"Loiseau","year":"2018","journal-title":"Eur Respir J"},{"issue":"169","key":"10.1016\/j.bulcan.2026.04.011_bib0785","doi-asserted-by":"crossref","first-page":"220251","DOI":"10.1183\/16000617.0251-2022","article-title":"Multiple breath washout and oscillometry after allogenic HSCT: a scoping review","volume":"32","author":"Sonneveld","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.011_bib0790","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.chest.2017.12.009","article-title":"Inert gas washout in bronchiolitis obliterans following hematopoietic cell transplantation","volume":"154","author":"Nyilas","year":"2018","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.bulcan.2026.04.011_bib0795","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.011_bib0800","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.healun.2013.02.004","article-title":"Pirfenidone: a potential therapy for progressive lung allograft dysfunction?","volume":"32","author":"Ihle","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"19","key":"10.1016\/j.bulcan.2026.04.011_bib0805","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/bloodadvances.2025016122","article-title":"Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease","volume":"9","author":"Sharifi","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.bulcan.2026.04.011_bib0810","first-page":"2932","article-title":"Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"141","author":"Koshy","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.011_bib0815","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.3390\/ijms25126731","article-title":"Repeated infusions of bone-marrow-derived mesenchymal stem cells over 8 weeks for steroid-refractory chronic graft-versus-host disease: a prospective, phase I\/II clinical study","volume":"25","author":"Kim","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2026.04.011_bib0820","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241254678","article-title":"A novel JAK1 inhibitor SHR0302 combined with prednisone for first-line treatment of chronic graft-versus-host disease: a phase I clinical trial","volume":"33","author":"He","year":"2024","journal-title":"Cell Transplant"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:22:17Z","timestamp":1785928937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":82,"alternative-id":["S0007455126003127"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge de la GVH chronique pulmonaire en 2025, indication de la transplantation pulmonaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}